Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference

Rhea-AI Summary

TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences (NASDAQ: PCRX) announced its participation in an analyst-led fireside chat at the Barclays Global Healthcare Conference on March 15, 2023, at 9:00 AM ET in Miami. The event will be accessible via the company’s website with a two-week replay available post-event.

Pacira focuses on non-opioid therapies, offering three commercial products: EXPAREL for postsurgical pain, ZILRETTA for osteoarthritis knee pain, and ioveraº for drug-free pain control. The company aims to reduce opioid reliance in pain management.

News Market Reaction – PCRX

-2.03%

-2.03% Session move

In the trading session that priced this news, PCRX declined 2.03%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 9:00 AM ET on Wednesday, March 15, 2023 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira         

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

FAQ

When is Pacira BioSciences participating in the Barclays Global Healthcare Conference?

Pacira BioSciences will participate in the Barclays Global Healthcare Conference on March 15, 2023, at 9:00 AM ET.

How can I access the live audio of Pacira's event?

You can access the live audio of Pacira's analyst-led fireside chat on their website.

What products does Pacira BioSciences offer?

Pacira BioSciences offers three commercial non-opioid products: EXPAREL, ZILRETTA, and ioveraº.

What is the purpose of Pacira's non-opioid treatments?

Pacira's non-opioid treatments aim to provide alternatives for pain management and reduce the reliance on opioids.

Will there be a replay of Pacira's fireside chat?

Yes, a replay of the webcast will be available for two weeks following the event.